Dr. Agarwal’s research is focused on exploring and enhancing recombinant adenoviral vectors and their use in gene therapy, centered on, but not limited to, cancer therapeutics. Her research group is developing novel tumor-selective oncolytic viruses to stimulate anti-tumor immune responses and chimeric antigen receptor T (CAR T) cells against cancer-specific cell surface antigens. Her research also includes the identification of cell surface receptors involved in Canine adenovirus type 2 (CAV2) binding and internalization and corresponding binding and internalization motifs of those receptors on CAV2 capsid. Lastly, another aspect of her research is to identify cancer-specific biomarkers from the liquid biopsy of cancer patients.